Literature DB >> 2423427

HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection.

M Pignatelli, J Waters, D Brown, A Lever, S Iwarson, Z Schaff, R Gerety, H C Thomas.   

Abstract

In a chimpanzee model of acute type B hepatitis, at the time of onset of hepatitis B virus replication and before the development of immunity to hepatitis B virus, interferon is present in the plasma. This is followed by an increase in the display of HLA class I, but not class II proteins, on the hepatocyte membrane. In chronic hepatitis B virus infection, there is a low density of HLA class I protein display on the infected hepatocyte. Administration of alpha-interferon enhances HLA display and in many cases is followed by a transaminase elevation, seroconversion of HBe antigen to antibody and disappearance of hepatitis B virus DNA from serum, changes implying clearance of infected hepatocytes. Successful response to interferon therapy may be predicted by a rapidly rising serum beta 2-microglobulin, a component of the HLA class I molecule, during the first 2 weeks of therapy, before the rise in transaminases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423427     DOI: 10.1002/hep.1840060303

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

1.  Soluble HLA class I antigens in sera of patients with chronic hepatitis.

Authors:  K Sakaguchi; N Koide; T Takenami; H Matsushima; H Takabatake; S Ferrone; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1992-04

Review 2.  Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response.

Authors:  G R Foster; H C Thomas
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

3.  Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection.

Authors:  T I Michalak; P D Hodgson; N D Churchill
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B.

Authors:  Danbi Lee; Young-Hwa Chung; Sae Hwan Lee; Yoon-Seon Lee; Don Lee; Jeong Eun Hwang; Kang Mo Kim; Young Suk Lim; Han Chu Lee; Eunsil Yu; Young Sang Lee; Dong Jin Suh
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

5.  HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease.

Authors:  G Ballardini; F B Bianchi; R Mirakian; M Fallani; E Pisi; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

6.  Serum concentrations of soluble HLA-class I and CD8 forms in patients with viral hepatic disorders.

Authors:  M Hagihara; T Shimura; K Takebe; B Munkhbat; K Hosoi; T Kagawa; N Watanabe; S Matsuzaki; K Yamamoto; K Sato; K Tsuji
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

7.  Development of granulomatous hepatitis during treatment with interferon-alpha 2b.

Authors:  A Propst; T Propst; O Dietze; H Kathrein; G Judmeier; W Vogel
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

8.  Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.

Authors:  R Wejstål; G Norkrans; O Weiland; R Schvarcz; D Fuchs; H Wachter; A Fryden; H Glaumann
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

9.  Hepatic HLA antigen display in chronic hepatitis B virus infection. Relation to hepatic expression of HBV genome/gene products and liver histology.

Authors:  J Y Lau; G L Bird; N V Naoumov; R Williams
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

10.  Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.

Authors:  G Zöhrens; T Armbrust; K H Meyer Zum Büschenfelde; G Ramadori
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.